The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as ...

"IgA nephropathy is a condition with an average age at diagnosis of around 40 years. 6 Due to disease progression, a patient's kidneys may fail. Treatments, such as sparsentan, that have been ...

Proteinuria is a major risk factor for IgA nephropathy progression ... CSL Vifor expects to launch sparsentan in the UK in the second half of 2025; commercial stock will be available from July ...

This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy.

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...